Insights 11/11/2025
Osteoporosis is a silent disease, often discovered only after a fracture occurs. With millions of people worldwide at risk, early and accurate diagnosis is crucial. While bone mineral density (BMD) remains the standard for assessing osteoporosis, it does not fully capture the complexity of bone strength and fracture risk.
This is where Trabecular Bone Score (TBS) has changed the game. By analyzing bone microarchitecture, TBS provides insights that BMD alone cannot. And now, with TBS Osteo Advanced, Medimaps is helping clinicians enhance osteoporosis diagnosis and fracture risk prevention by offering additional clinical benefits, improved connectivity and streamlined operational efficiency.
The role of TBS in osteoporosis diagnosis
Traditional DXA scans measure BMD, giving clinicians an essential metric. However, many patients with “normal” or “osteopenic” BMD still suffer fragility fractures. This diagnostic gap has highlighted the need for better assessment tools.
TBS complements BMD by:
- Offering an indirect measure of bone microarchitecture.
- Enhancing fracture risk prediction beyond density.
- Stronger clinical decision-making when BMD results alone are inconclusive.
Many studies have validated TBS, making it an indispensable companion to BMD in osteoporosis treatment, bone health management, and fracture risk assessment.
What makes the next generation of TBS Osteo different?
TBS Osteo Advanced: The Next Generation of TBS Osteo is more than an upgrade – it is a comprehensive enhancement of Medimaps’ proven TBS technology. Its features include:
- Additional clinical benefits: accounting for more body size phenotypes and reaching more of the patient population
- Improved connectivity: ensuring secure real-time access to TBS reports on devices within the hospital network
- Streamlined operational efficiency: offering easy DXA fleet management, and customizable and harmonized reporting
By integrating seamlessly into osteoporosis screening protocols, this solution supports earlier intervention, optimized treatment decisions, and improved fracture prevention outcomes.
Why it matters for clinicians and patients
The benefits of TBS Osteo Advanced extend across the healthcare ecosystem:
- For clinicians: more confidence in diagnostic decisions, stronger fracture risk prediction, better support for treatment planning, and improved workflow efficiency.
- For patients: earlier identification of osteoporosis, more personalized care, and potentially fewer fractures thanks to targeted treatment.
- For healthcare systems: reduced fracture-related costs and fewer hospitalizations.
When combined with BMD and integrated into FRAX score calculations, TBS provides a multidimensional approach to bone health — one that bridges the gap between bone density and bone quality.
BMD + TBS: A complementary approach
It’s important to emphasize: TBS does not replace BMD. Instead, it complements it.
- BMD measures the amount of bone mineral.
- TBS measures bone microarchitecture.
This dual approach provides the most reliable assessment of fracture risk, empowering physicians to decide when preventive treatment is necessary and when osteoporosis treatment guidelines should be updated.
Evidence-based impact of Trabecular Bone Score
More than 1,500 peer-reviewed studies confirm that the Trabecular Bone Score (TBS) is a powerful, independent predictor of fragility fractures, complementing bone mineral density in ways that DXA alone cannot. Additionally, TBS is recommended in more than 30 national and international guidelines.
Clinical evidence shows that when TBS iNsight™(TBS Osteo) is integrated into FRAX calculations, fracture risk prediction becomes significantly more accurate across age groups, sexes, and ethnicities. Importantly, low TBS values are strongly linked with increased fracture risk in secondary osteoporosis, including diabetes, chronic kidney disease, and long-term glucocorticoid therapy, even when bone density values appear normal.
With the launch of TBS Osteo Advanced, clinicians now have access to additional clinical benefits, improved connectivity and streamlined operational efficiency, making it easier to apply this validated biomarker in everyday practice.
Together, BMD, FRAX, and TBS offer a comprehensive view of bone health that supports better osteoporosis treatment decisions, more targeted fracture prevention, and improved long-term patient outcomes.
Medimaps’ commitment to innovation
TBS Osteo Advanced is part of Medimaps’ mission to deliver advanced imaging biomarkers that empower clinicians and improve patient outcomes. From research validation to clinical adoption, Medimaps continues to invest in solutions that bridge the gap between science and practice.
With a strong emphasis on osteoporosis diagnosis and fracture prevention, Medimaps provides tools that bring confidence to both healthcare providers and patients.
💡 Ready to see the difference?
Download our whitepaper and discover how the next generation of TBS Osteo is redefining osteoporosis diagnosis, DXA bone health insights, and fracture risk prediction.
